Childress Capital Advisors LLC purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 315 shares of the pharmaceutical company’s stock, valued at approximately $74,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Griffin Asset Management Inc. raised its holdings in Vertex Pharmaceuticals by 3.6% in the 4th quarter. Griffin Asset Management Inc. now owns 3,744 shares of the pharmaceutical company’s stock valued at $885,000 after buying an additional 129 shares during the last quarter. US Bancorp DE raised its holdings in Vertex Pharmaceuticals by 7.0% in the 4th quarter. US Bancorp DE now owns 14,108 shares of the pharmaceutical company’s stock valued at $3,334,000 after buying an additional 922 shares during the last quarter. IFM Investors Pty Ltd raised its holdings in Vertex Pharmaceuticals by 13.6% in the 4th quarter. IFM Investors Pty Ltd now owns 24,974 shares of the pharmaceutical company’s stock valued at $5,902,000 after buying an additional 2,997 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Vertex Pharmaceuticals by 18.9% in the 4th quarter. Victory Capital Management Inc. now owns 657,200 shares of the pharmaceutical company’s stock valued at $155,323,000 after buying an additional 104,471 shares during the last quarter. Finally, Congress Asset Management Co. MA raised its holdings in Vertex Pharmaceuticals by 3.6% in the 4th quarter. Congress Asset Management Co. MA now owns 312,428 shares of the pharmaceutical company’s stock valued at $73,839,000 after buying an additional 10,938 shares during the last quarter. Institutional investors own 92.17% of the company’s stock.

In other news, EVP Bastiano Sanna sold 1,686 shares of the company’s stock in a transaction dated Monday, April 5th. The stock was sold at an average price of $214.14, for a total transaction of $361,040.04. Following the sale, the executive vice president now directly owns 36,223 shares in the company, valued at $7,756,793.22. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Michael Parini sold 400 shares of the company’s stock in a transaction dated Wednesday, February 3rd. The shares were sold at an average price of $216.56, for a total value of $86,624.00. Following the sale, the executive vice president now owns 35,276 shares in the company, valued at $7,639,370.56. The disclosure for this sale can be found here. Insiders sold a total of 7,200 shares of company stock worth $1,533,052 over the last 90 days. 0.70% of the stock is currently owned by company insiders.

VRTX has been the subject of a number of research reports. BMO Capital Markets dropped their price objective on shares of Vertex Pharmaceuticals from $302.00 to $284.00 and set an “outperform” rating for the company in a report on Tuesday, February 2nd. JPMorgan Chase & Co. restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, December 11th. SVB Leerink lowered their price target on shares of Vertex Pharmaceuticals from $257.00 to $250.00 and set a “market perform” rating for the company in a report on Tuesday, February 2nd. Piper Sandler raised their price target on shares of Vertex Pharmaceuticals from $307.00 to $347.00 and gave the stock an “overweight” rating in a report on Tuesday, February 2nd. Finally, HC Wainwright lowered their price target on shares of Vertex Pharmaceuticals from $315.00 to $275.00 and set a “buy” rating for the company in a report on Tuesday, February 2nd. Four research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. Vertex Pharmaceuticals presently has an average rating of “Buy” and an average price target of $293.13.

Shares of Vertex Pharmaceuticals stock opened at $212.72 on Thursday. Vertex Pharmaceuticals Incorporated has a 52-week low of $202.57 and a 52-week high of $306.08. The stock’s 50-day simple moving average is $213.50 and its 200 day simple moving average is $226.85. The stock has a market capitalization of $55.30 billion, a P/E ratio of 26.86, a P/E/G ratio of 1.25 and a beta of 0.79. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.60 and a current ratio of 3.72.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Sunday, January 31st. The pharmaceutical company reported $2.51 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.59 by ($0.08). Vertex Pharmaceuticals had a net margin of 38.51% and a return on equity of 28.55%. The firm had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same quarter in the prior year, the firm posted $1.70 earnings per share. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 8.5 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene.

Featured Story: What is the yield curve?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.